SyntheMed REPEL-CV Receives Russian Approval
SyntheMed announced that its REPEL-CV barrier has received approval from the Ministry of Health of the Russian Federation for use in all patients who undergo open heart surgery.
595
SyntheMed Receives Endorsement, New Patent
REPEL-CV, a bioresorbable anti-adhesion barrier developed by biomaterials company SyntheMed, has received an endorsement from Kids with Heart.